DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: LEMTRADA (Campath, alemtuzumab)
       *****************************************************
       #Post#: 1197--------------------------------------------------
       (AAN) 10-year follow-up data on Lemtrada
       By: agate Date: April 28, 2016, 2:08 pm
       ---------------------------------------------------------
       From Medical News Today, April 20, 2016:
       [quote]Multiple sclerosis: 10-year follow-up data on Lemtrada
       (alemtuzumab) presented at the AAN 2016 Annual Meeting
       Adapted Media Release
       Sanofi Genzyme, the specialty care global business unit of
       Sanofi, has announced that a new long-term analysis detailing 10
       years of clinical efficacy of Lemtrada® (alemtuzumab) in people
       with relapsing-remitting multiple sclerosis (RRMS) will be
       presented at the 68th American Academy of Neurology (AAN) 2016
       Annual Meeting in Vancouver, Canada, 15-21 April 2016.
       Results from the on-going, long-term extension study of the
       phase 2 CAMMS223 study showed that over 10 years of follow-up,
       76 percent of patients were shown to be free from 6-month
       confirmed disability worsening (increase of ≥1.0 EDSS
       point [or ≥1.5 points if baseline EDSS=0]) and 78 percent
       had an Expanded Disability Status Scale [EDSS] score that was
       either stable or showed greater than or equal to one point
       improvement in EDSS vs baseline.
       In addition, a low annualised relapse rate (ARR) was maintained
       (0.08) over the period. The long-term safety observed in this
       group of patients was in line with that of other Lemtrada
       clinical trials.
       People who entered the CAMMS223 study had not previously
       received other treatments for RRMS and the majority of those who
       were followed for 10 years received a maximum of three courses
       of Lemtrada.
       "These data provide further evidence of the long term response
       with Lemtrada in treatment-naïve patients with
       relapsing-remitting MS", said Professor Alasdair Coles, Lead
       Investigator, University of Cambridge School of Clinical
       Medicine, Cambridge, UK. "It is remarkable that such infrequent
       dosing with Lemtrada offers stability or improvement of
       disability over ten years. These findings confirm that Lemtrada
       is a valid treatment approach for people with multiple
       sclerosis, without the need for continuous treatment."
       "We are very pleased with these new data, which are part of our
       extensive clinical development programme and our commitment to
       the field of MS," commented Peter Kuiper, General Manager UK &
       Ireland at Sanofi Genzyme. "Being able to offer this treatment
       option, which was discovered and developed in the UK to
       clinicians and their patients, is of incredible importance to
       us."
       The data on Durable Efficacy of Alemtuzumab Over 10 Years:
       Long-Term Follow-Up of Patients with RRMS from the CAMMS223
       Study was presented as a poster presentation on Monday, 18 April
       2016.
       More than 100,000 people in the UK have Multiple Sclerosis (MS),
       with around 85 percent diagnosed with RRMS. Lemtrada is the
       second of Sanofi Genzyme's treatments for MS to receive approval
       for use from NICE and on the NHS in England and Wales.[/quote]
       [References omitted]
       The article can be seen here
  HTML http://www.medicalnewstoday.com/releases/309335.php.
       *****************************************************